• Metadoro
  • Products
  • News and analysis

News and analysis

Check market insights shared by our community members
09.01.2025
VeChain Is Suffering on Rising Borrowing Costs

VeChain (VET) has fallen 12.7% this week, trading at $0.0445, underperforming the broader cryptocurrency market. Bitcoin (BTC), the leading cryptocurrency, has declined by 5.6% to $93,220, with bearish momentum building as it approaches key support at $89,000-$91,000. This decline is largely attributed to tightening monetary conditions in the United States, which continue to weigh on risk assets. Investor confidence is further shaken by significant net outflows from spot BTC-ETFs, which lost $583 million on Wednesday, marking the second-largest single-day outflow on record.

If BTC falls below the critical support level of $89,000-$91,000, VeChain is likely to extend its losses, with prices potentially declining another 10% to $0.0400. A sustained drop in BTC could push VET even lower, towards $0.0300. Conversely, a strong rebound in BTC prices to the $100,000 level could drive VET back up to $0.0500, representing a recovery of approximately 12% from current levels.

23.01.2025
Ontology Is Sliding Towards $0.2000

Ontology (ONT) is down 2.3% this week, trading at $0.2176, in line with the broader crypto market where Bitcoin (BTC) has declined 2.0% to $101,632. While the new U.S. administration has made some strides toward fairer crypto regulation, Donald Trump has remained silent on the highly anticipated issue of adding Bitcoin to U.S. federal reserves.

Market speculation is rampant, with figures like BlackRock CEO Larry Fink suggesting Bitcoin could surge to $700,000 per coin if sovereign wealth funds begin accumulating. Other forecasts predict Bitcoin reaching $250,000 by year-end. While such projections could foster optimism, the lack of decisive action or announcements regarding U.S. crypto reserves is weighing heavily on the market.

For Ontology, the situation remains bearish. Having breached the critical support at $0.2500 last week, the token is now approaching the $0.2000 level. A failure to provide clear evidence or statements about U.S. federal crypto reserve plans could see ONT fall even further, breaching the $0.2000 mark and deepening its losses.

14.01.2025
Merck Becomes Interesting to Be Added to a Portfolio

Merck & Co (MRK) stocks have shown signs of becoming a compelling buy opportunity. Over the past six months, the stock has been in a downtrend, declining 29.8% to $94.50 per share. However, since mid-November, MRK has demonstrated a reversal of momentum, rebounding by 10.0% to reach $104.87 on December 5. Following a brief pullback and consolidation period, the stock has retested the downtrend resistance and appears poised to continue its upward trajectory.

With prices currently positioned to target $110.00, this represents a potential 9-10% upside from the present levels. Setting a stop-loss at $93.50 aligns with a prudent risk management strategy, providing protection against further downside while allowing for upside potential. The recent consolidation phase further supports the case for a breakout, making this an attractive moment to consider initiating or adding to a position in MRK.

16.01.2025
Delta Is Taking Off To Update Its Highs

Delta Air Lines stock rose markedly by low double digits in the first ten days of the new year. The U.S. carrier has served more than 200 million customers in 2024, when it was also recognized by J.D. Power, a leading American data analytics and consumer intelligence company, for being No. 1 in First/Business and Premium Economy Passenger Satisfaction. Travelers became more willing to spend extra money for swanky seats when meeting a high level of service. Delta is just positioning itself as the nation's premium airline. And what's more important, its Christmas quarter's earnings reportedly surpassed average analyst pool projections. Driven by stronger travel demand, smart financial management and capacity discipline, Delta business provided last three-months' profit of $1.85 per share vs $1.28 at the same period one year ago, compared to $1.75 in consensus estimates. On January 10, the airline industry leader put its future profit levels within a range between $0.70 and $1 per share in the current quarter through the end of March, while analyst expectations were focused on $0.77 cents, according to data compiled by LSEG. The starting months of each year always perform worse. It is clear that all carriers made losses in the Covid years of 2020-2022, but Delta profits only recovered into a range from $0.25 to $0.45 in the first quarter of 2023 and 2024, respectively, but Q1 profit numbers varied from $0.75 to $0.96 even in the three blessed years before the pandemic. Delta added that it is forecasting annual earnings in excess of $7.35 a share, which would be the highest in its 100-year history, based on its planned revenue growth of 7% to 9% in the March quarter from a year ago. The announcement could be compared to an adjusted profit of $6.16 a share in 2024. The company happily breaks through ticket prices' rising effects, almost undisturbed by a reduction in airline seats in the domestic market, which was peculiar for most carriers. Thus, new expectations created a fertile ground for setting new price records, even though price movements on Delta charts look most convincing among its other American rivals.

By the way, Citigroup analysts freshly updated their outlook on Delta Air Lines shares to raise their price target to $80 from the previous $77, vs the actual range around $65 per share where the stock just came after a reasonable market correction from last week's and all-time highs. Citigroup said it has included factors like higher revenue per available seat mile, projections of slightly lower fuel prices, increased taxation, a minor rise in share count, and the incorporation of fourth-quarter 2024 results into their financial model, which has projected Delta's profit at $7.49 per share in 2024 and $8.72 in 2025. Delta shares are Buy-rated at Citi, and we agree with their positive estimates in general, while keeping in mind even better price goals somewhere between $82.5 and $85.

14.01.2025
Tezos Is Seen Hodling above $1.200

Tezos (XTZ) has declined slightly by 0.2% this week, trading at $1.249, following Bitcoin’s (BTC) drop to $89,158, which triggered widespread altcoin sell-offs due to concerns of a potential further decline in BTC to $80,000. However, Bitcoin managed to hold above the critical support level at $89,000-$91,000, offering some relief to the broader crypto market.

Speculation about a shift in U.S. trade policy has provided additional support to crypto assets. Reports suggest the new U.S. administration may pursue a gradual increase in tariffs rather than an abrupt hike, which could help alleviate inflationary pressures and lead to a less aggressive monetary stance from the Federal Reserve.

This development is a positive signal for the cryptocurrency market and may help Tezos maintain its position above the key support level of $1.200.

Three Most Trusted Dividend Companies: Kinder Morgan

Kinder Morgan is one of the largest energy companies in the United States and is considered to be a safe haven asset amidst current turbulent environment. KMI stocks are traded 11% off their peak values of the last two years, while its dividend yield is at 6.5%. The world has faced a strong energy crisis and there are no doubts KMI services will be in demand in the foreseeable future.

Kinder Morgan has increased its distributable cash flow by 15% to $1,176 million amid high energy prices. Better-than –expected financial conditions of its clients suggest that upcoming contracts could be signed on better financial conditions. In other words, KNO stocks are not overreacting on rising energy prices and may be better secured if energy prices would go down.

The company made buy backs on $275 million of its stocks in the market, or 0.7% of total free float stocks. This could be considered to be an additional reward for investors aside of regular dividends. KMI stocks are unlikely to perform a strong surge in the near future but could be considered as safe haven assets with high dividends for long term-investors who are willing to weather elevated market turbulence.

3032
Three Most Trusted Dividend Companies: JPMorgan Chase

JPM shares are trading 30% off their peak prices. Its net profit hit $9.7 billion in the last quarter compared with $8.6 billion in the previous one. Rising interest rates could significantly support its banking business, helping loans generate a decent amount of profit. The deposit margin in the Q3 2022 rose to 1.83% year-on-year from 1.29% a year before.

The Credit Adequacy Ratio (CAR), which indicates a bank’s available capital and it the most adequate measurement that represent all assets, including the risky ones, is rarely published. Instead, the Common Equity Tier 1 (CET1) capital is disclosed that is based only on common stocks, net surplus and other accrued revenues. CET1 should be above 4.5%, while JPM has it at 12.5% and it is going to be increased to 13% by the beginning of 2023. The bank is planning to resume active buy backs in 2023. JPM stocks dividend yield is at 3.6%, while P/E ratio is at 10, which is considered to be attractively low for such kind of assets.

4225
The Two Most Oversold Medical Cannabis Stocks: Canopy Growth

CGS stock prices are 9% off their peaks. But a looser tax regulation may boost business margins and some investors consider the moment to be appropriate to buy such stocks. According to federal regulations in the United States marijuana or cannabis with more than 0.3% THC is a Schedule 1 drug, the same as heroin, LSD, ecstasy and magic mushrooms. Cocaine and methamphetamine are considered less harmful and are put into the Schedule 2 group. This classification is seriously bounding any promotions of cannabis related products and hampering cannabis producers’ profits. The U.S. Federal law prevents any deduction of related costs, pushing the effective tax rate up to 90%. So, any loosening of taxation and a change of drug classification would greatly benefit cannabis producers.

Tilray reported revenues of Can$122.8 million and a negative gross margin of Can$1.3 million during the last quarter. So, there are no illusions that the majority of cannabis-related business are making a loss. However, potential profits after stocks lose most of their value may be huge even considering existing risks. CGS stocks are traded at $2.4, a price lastly seen in the summer of 2016, before the bubble emerged in this sector. The recovery of stock prices to the levels of early 2022 would mean stock prices up by 300%.

3273
The Two Most Oversold Medical Cannabis Stocks: Tilray

TLRY stocks are trading 95% off their peak prices. The return to these values recorded in March 2022 would mean a 200% profit. Tilray is one of the most popular companies in the cannabis sector among institutional and retail investors. But inflated expectations led to a bubble in the cannabis sector that burst in 2019. Since then, cannabis-related stocks have been sliding within the bearish trend. New federal government initiatives in the United States may seriously exhilarate the industry.

TLRY reported revenues up by 8% to $153.3 million for the recent quarter, with net losses at $65.7 million amid depreciation of inventories. The company has acquired the rival Alpria to reduce costs by $80 million by the end of 2023. The strategic merger with HEXO is close to being finalised. That would generate a positive free cash flow in 2023, according to Tilray’s management statement. Together with looser restrictions in the U.S. Tilray stocks may gain positive momentum.

4076
317

Join our community

Share your professional and amateur observations, exchange experiences, anticipate developments

Category
All
Stocks
Crypto
Etf
Commodities
Indices
Currencies
Energies
Metals
Instruments
Author
All
Metadoro
Contributors